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Abstract
Background: Preeclampsia is associated with the placental release of soluble fms-like tyrosine kinase 1 (sFlt-1)
and soluble endoglin (sENG). These anti-angiogenic factors cause hypertension and multi-organ injury. Pravastatin
decreases placental secretion of sFlt-1 in vitro and is currently being examined in clinical trials as a potential
treatment for preeclampsia. However, it is possible that different classes of statins may be more potent at
decreasing sFlt-1 secretion. We compared the relative potency of three different generations of statins on sFlt-1
and sENG secretion from human endothelial cells, trophoblast cells, and placenta explants.
Methods: We performed functional experiments using primary human umbilical vein endothelial cells,
trophoblast cells and preterm preeclamptic placental explants to assess the affect of simvastatin, rosuvastatin and
pravastatin on sFlt-1 and sENG secretion and compared the relative potency of each statin at reducing these
factors (Inhibitory Concentration 50). Furthermore we assessed the effect of each statin on the antioxidant and
cytoprotective enzyme, heme-oxygenase 1.
Results: All statins reduced sFlt-1 secretion from endothelial cells, trophoblasts and preterm preeclamptic
placental explants. Simvastatin was the most potent inhibitor of sFlt-1 secretion from endothelial cells (IC 50
3.2 μM), trophoblast cells (IC 50 61.4 μM) and placental explants. Simvastatin was 28 times and 3 times more
potent at reducing sFlt-1 secretion from endothelial cells and 85 times and 33 times more potent at reducing
sFlt-1 secretion from trophoblast cells than pravastatin or rosuvastatin respectively.
All statins increased sENG secretion from endothelial cells however did not change secretion from placental
explants.
While all statins up-regulated heme-oxygenase 1 in endothelial cells, only simvastatin up-regulated its expression
in placenta from patients with preterm preeclampsia.
Conclusion: Simvastatin may be a more potent inhibitor of sFlt-1 secretion from endothelial cells, trophoblast
cells and placenta from women with preterm preeclampsia than either pravastatin or rosuvastatin.
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Background
Preeclampsia is associated with the placental release of
soluble fms-like tyrosine kinase 1 (sFlt-1) [1] and soluble
endoglin (sENG) [2] into the maternal circulation lead-
ing to hypertension, proteinuria and multi-system organ
injury [3–7]. Currently there is no medical treatment
that stabilises the disease pathophysiology and delivery,
often at preterm gestations, is required to stop maternal
disease progression [3, 4]. A therapeutic that stabilises
the maternal disease process allowing preterm preg-
nancy continuation, or reducing progression to severe
disease at term, would be beneficial [8].
Pravastatin has been proposed as a therapeutic candi-
date for preeclampsia [9–14]. It has been shown to re-
duce the preeclamptic phenotype in 4 different animal
models of the disease [11–14]. We recently published a
case series showing administration of pravastatin may
stabilise biochemical features of the disease in 3 out of 4
cases of preterm preeclampsia [10]. We, and others have
also shown pravastatin [10] and simvastatin [9] reduce
sFlt-1 secretion from human placental tissue. This is a
desirable feature of a preeclampsia therapeutic as sFlt-1
is a likely pathogenic protein of the disease [1]. Firstly,
sFlt-1 is elevated in patients presenting with preeclamp-
sia [15] compared to levels in normal pregnancy and
secondly, when injected or overexpressed in mice and
rats, hypertension and proteinuria occur [1, 2]. Impor-
tantly, when sFlt-1 levels were reduced in preeclamptic
patients by plasma apheresis, there was a possible stabi-
lisation of disease [16].
Pravastatin [10] and simvastatin [9] have both been
shown to exert an effect on sFlt-1 secretion by inhibiting
HMG CoA reductase, a key enzyme in the cholesterol
synthesis pathway. There are many statins and they are
divided into three different generations based on their
relatively potencies in reducing low density lipoproteins,
a surrogate marker for their inhibition of HMG CoA re-
ductase [17]. It is therefore conceivable that more potent
inhibitors of HMG CoA reductase, might produce
greater reductions in sFlt-1 secretion.
Pravastatin is a first generation statin and in fact one
of the least potent inhibitors of HMG CoA reductase
[17]. Simvastatin is a second generation statin and a
more potent inhibitor, whilst rosuvastatin is the most
potent inhibitor of HMG CoA reductase and sole third
generation statin [17]. Whilst in vivo studies [11–14]
and clinical trials [18, 19] have focused on pravastatin as
a preeclampsia therapeutic, it is conceivable that simva-
statin or rosuvastatin might have a more pronounced ef-
fect on decreasing sFlt-1 secretion.
We compared the potency of simvastatin, rosuvastatin
and pravastatin on sFlt-1 and sENG secretion in vitro
using human endothelial cells, trophoblast cells and
placental explants obtained from women with preterm
preeclampsia. We assessed whether statins induced the
cytoprotective enzyme, heme-oxygenase 1.
Methods
Ethics approval was obtained from the Mercy Health
Human Research Ethics Committee and all women gave
written informed consent prior to the collection and use
of placenta and umbilical cord.
Isolation and treatment of primary human umbilical vein
endothelial cells (HUVECs)
Umbilical cords were collected from normal term pla-
centas. The cord vein was infused with 10 ml (1 mg/ml)
of collagenase (Worthington, Lakewood, New Jersey)
and cells isolated as previously described [20]. Cells were
cultured in M199 media (Life Technologies, Victoria,
Australia) containing 10 % FCS (Sigma, St Louis, United
States), 1 % antibiotic-antimycotic (Life Technologies)
and 20 μg/ml endothelial cell growth factor (ECGS)
(Sigma) and 100 μg/ml heparin (Sigma) and used be-
tween passages 2 to 4. Cells were plated at 24,000 /cm2
and treated at 80 % confluency with 0, 1, 2 or 5 μM
simvastatin or rosuvastatin and 0, 2, 5 or 200, μM
pravastatin for 24 h. Conditioned media was collected
for assessment of sFlt-1 and sENG secretion and cell
lysates collected for RNA extraction.
Isolation and treatment of primary human trophoblast
cells
Term placentas were collected from women having
elective caesarean sections. Human trophoblasts were
isolated as previously described [20, 21]. Primary tropho-
blasts were cultured in DMEM high Glutamax (Life
Technologies) containing 10 % FCS and 1 % antibiotic-
antimycotic (Life Technologies) on fibronectin (10 μg/
mL; BD Biosciences, New South Wales, Victoria) coated
plates. Cells attached over 24 h before being washed in
PBS [20]. Cells were treated with 0, 5, 50, 100 μM simva-
statin, 0, 100, 200, 300 μM rosuvastatin or 0, 20, 200,
2000 μM pravastatin for 24 h under 8 % O2 and 5 %
CO2 at 37 °C. Conditioned media was collected to assess
sFlt-1 secretion.
Cell viability assay (MTS assay and calcein stain)
Cell viability assay were performed using CellTiter
96-Aquesous One solution (Promega, Madison WI) or
calcein stain (Merk Millipore, Darmstadt, Germany)
according to the manufacturer’s instructions. Fluostar
omega fluorescent plate reader (BMG labtech,
Victoria, Australia) was used to detect fluorescence
(quantify adhesion).
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Placental explant culture
Human placental tissue was collected from three
women with severe early onset preeclampsia (delivered
at ≤34 weeks gestation). Preeclampsia was defined
using the 2013 American College of Obstetricians and
Gynecologists (ACOG) guidelines: the presence of
hypertension >140/90 on two occasions 4 h apart and
any of the following: proteinuria >300 mg/day, renal in-
sufficiency, impaired liver function, thrombocytopenia
or visual disturbance [22].
Villous explants were prepared as previously described
[10, 20] and cultured in DMEM high glutamax (Life
Technologies) containing 1 % antibiotic-antimycotic
(Life Technologies) and 10 % fetal calf serum (FCS)
(Sigma). After 24 h placental explants were treated with
0, 100 μM simvastatin, 0, 100 μM rosuvastatin or 0,
2000 μM pravastatin (Sigma) for 72 h under 8 % O2 and
5 % CO2 at 37 °C. To assess sFlt-1 and sENG secretion,
protein levels were normalized against wet placental ex-
plant weights. Tissue was collected for RNA extraction.
ELISA analysis
Concentrations of sFlt-1 and sENG were measured in
conditioned cell/tissue culture media using the DuoSet
VEGF R1/Flt-1 kit (R&D systems by Bioscience, Water-
loo, Australia) and a DuoSet Human Endoglin CD/105
ELISA kit (R&D systems) according to manufacturer’s
instructions.
RT-PCR
RNA was extracted from placental explants and
HUVECs using an RNeasy mini kit (Qiagen, Valencia,
CA) and quantified using the Nanodrop ND 1000 spec-
trophotometer (NanoDrop technologies Inc, Wilmington,
DE). 0.2 μg of RNA was converted to cDNA using Super-
script VILO cDNA synthesis kit (Life Technologies) as
per manufacturer guidelines.
A taqman gene expression assay was performed for
heme-oxygenase 1 (Life Technologies). Primer sequence
for heme-oxygenase 1 was forward primer 5′-GGAG
GAGGAGATTGAGCACAACA-3′ and reverse primer
5′-AGCGGTACAGCTGCTTGAAC-3′. RT-PCR was
performed on the CFX 384 (Bio-Rad, Hercules, CA)
using FAM-labeled Taqman universal PCR mastermix
(Life Technologies) with the following run conditions:
50 °C for 2 min; 95 °C for 10 min, 95 °C for 15 s, 60 °C
for 1 min (40 cycles). Sybr gene expression assay for
sFlt-1 e15a and sFlt-1 i13 was used. Primers for sFlt-1
e15a (forward 5′-CTCCTGCGAAACCTCAGTG-3′ and
reverse 5′-GACGATGGTGACGTTGATGT-3′) and sFlt-
1 i13 (forward 5′-ACAATCAGAGGTGAGCACTGCAA-
3′ and reverse 5′TCCGAGCCTGAAAGTTAGCAA-3′)
were designed as previously described (Geneworks, South
Australia, Australia) [23]. RT-PCR was performed
using the following run conditions: 95 °C for 20 min;
95 °C for 0.01 min, 60 °C for 20 min, 95 °C for 1 min
(39 cycles), melt curve 65 °C to 95 °C at 0.05 °C incre-
ments at 0.05 s.
All data were normalized to GAPDH as an internal
control and calibrated against the average Ct of the con-
trol samples. GAPDH mRNA expression was stable in
control compared to statin treatment groups. Results are
expressed as fold change from control.
Statistical analysis
Technical replicates were performed in triplicate for
each experiment, with a minimum of three separate
experiments repeated for each in vitro study. Data
was tested for normal distribution and statistically
analysed as appropriate. When three or more groups
were compared a 1-way ANOVA (for parametric data)
or Kruskal-Wallis test (for non-parametric data) was
used. Post-hoc analysis was carried out using either
the Tukey (parametric) or Dunn’s test (non-paramet-
ric). When two groups were analysed, either an un-
paired t-test (parametric) or a Mann-Whitney test
(non-parametric) was used. All data is expressed as
mean ± SEM.
The IC50 values were determined by plotting the ef-
fect of the three statins on sFlt-1 secretion on the same
graph. Doses of the statins were transformed and the log
of the value recorded. The maximum, minimum and
slope of the curve were shared between data sets and
non-linear regression was performed. P-values <0.05
were considered significant. Statistical analysis was per-
formed using GraphPad Prism 6 software (GraphPad
Software, La Jolla, CA).
Results
Statin treatment of endothelial cells, primary trophoblasts
and placental explants obtained from patients with
preterm preeclampsia
We have previously reported the effect of pravastatin on
endothelial cells, primary trophoblasts and preeclamptic
placental explants [10]. Here we dose matched prava-
statin to simvastatin and rosuvastatin and also included
a dose that has an effect on sFlt-1, in order to perform a
comparison of potency. The doses were chosen based on
an ability to exert an effect on sFlt-1 whilst maintaining
cell viability. Cell viability was maintained for all statins
at the doses used in both placental and endothelial cells,
except for 5 μM simvastatin treatment of endothelial
cells, which reduced metabolic activity (a measure of cell
viability) by 17 % (data not shown). Experiments using
the three different statins were performed on the same
tissues at the same time so comparisons could be made.
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Simvastatin is the most potent inhibitor of sFlt-1 secretion
from primary endothelial cells
We first examined the effect of simvastatin, rosuvastatin
and pravastatin on sFlt-1 secretion from primary human
umbilical vein endothelial cells (HUVECs). All statins in-
duced a significant dose dependent reduction in sFlt-1
secretion from primary HUVECs (Fig. 1A). Simvastatin
was the most potent inhibitor of sFlt-1 secretion with an
IC50 (concentration of the drug required to reduce
secretion by 50 %) of 3.1 μM. This was 28 fold more
potent than pravastatin (IC50 88.5 μM) and 3 fold more
potent than rosuvastatin (IC50 8.9 μM) (Fig. 1B).
Next we explored the effect of the different statins on
the expression of two isoforms of sFlt-1. sFlt-1 is com-
prised of a number of different splice variants that differ
in sequence at the c-terminal region. The most abundant
variant in preeclampsia is sFlt-1 e15a which is primate
specific and accounts for >80 % of sFlt-1 secreted from
the placenta [24]. sFlt-1 i13 is the dominant sFlt-1 vari-
ant secreted by the endothelium [24]. We investigated
whether the different generations of statins altered sFlt-1
e15a or i13 mRNA expression in primary HUVECs. All
statins significantly reduced sFlt-1 e15a expression
(Fig. 1C). Simvastatin also significantly reduced sFlt-1
i13 mRNA expression whilst pravastatin and rosuvasta-
tin did not show any effect (Fig. 1D).
Simvastatin is the most potent inhibitor of sFlt-1 secretion
from primary trophoblasts and preeclamptic explants
We next compared the effect of the different statins on
sFlt-1 secretion from primary trophoblasts. All statins
significantly reduced sFlt-1 secretion from primary tro-
phoblasts at top doses (Fig. 2A). Simvastatin was the
most potent inhibitor of sFlt-1 secretion with an IC50 of
61.4 μM. It was 33 times more potent than rosuvastatin
(IC50 2029 μM) and 85 times more potent than prava-
statin (IC50 5224 μM) (Fig. 2B).
We also investigated the effects of the different statins on
sFlt-1 secretion from placental explants obtained from pa-
tients with preterm preeclampsia (Fig. 2C). Simvastatin was
a more potent inhibitor of sFlt-1 secretion whilst at the
same dose rosuvastatin did not show any effect and prava-





Fig. 1 Effects of statins on sFlt-1 secretion and mRNA expression of
isoforms e15a and i13 expression in primary HUVECs. a Simvastatin (0,
1, 2, 5 μM) rosuvastatin (0, 1, 2, 5 μM) and pravastatin (0, 2, 5, 200 μM)
reduce sFlt-1 secretion from primary HUVECs. b Inhibitory concentration
of sFlt-1 at 50 % (IC50) for simvastatin, rosuvastatin and pravastatin
was determined. c Pravastatin, simvastatin and rosuvastatin reduce
sFlt-1 e15a mRNA expression from primary HUVECs. d Simvastatin re-
duces sFlt-1 i13 mRNA expression from HUVECs whilst pravastatin
and rosuvastatin have no effect. Data represents n = 3 separate
experiments and is expressed as mean ± SEM. Dark blue bars= control,
light blue bars = statin treatments. b = p < 0.01, d = p < 0.0001
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In the same preterm preeclamptic explants, simva-
statin and rosuvastatin did not change sFlt-1 e15a ex-
pression, however pravastatin significantly reduced its
expression at a dose of 2000 μM (Fig. 2D).
All statins increase soluble endoglin (sENG) secretion
from endothelial cells and do not affect secretion from
placental explants
We next compared the effect of the statins on secretion
of sENG from primary endothelial cells, and placental
explants obtained from women with preterm preeclamp-
sia. Previously we have shown that pravastatin signifi-
cantly increases sENG secretion from endothelial cells
[10], and here we show that simvastatin and rosuvastatin
also increased its secretion. Simvastatin was the most
potent inducer of sENG secretion followed by rosuvasta-
tin and then pravastatin (Fig. 3A). In contrast, as previ-
ously demonstrated with pravastatin [10], there was no
change in sENG secretion from placental explants from
patients with preterm preeclampsia treated with the
simvastatin or rosuvastatin (Fig. 3B).
All statins upregulate heme-oxygenase 1 in primary
endothelial cells
Preeclampsia is thought to be associated with increased
oxidative stress [3]. Therefore it would be beneficial if
statins could up-regulate endogenous antioxidant
defenses. We have previously shown pravastatin up-
regulates heme-oxygenase 1 in endothelial cells how-
ever has no effect on its expression in placental
explants [10]. Here we assessed whether simvastatin
and rosuvastatin regulate heme-oxygenase 1 expression
in either endothelial cells or placental explants from
women with preterm preeclampsia. Indeed, we found
all statins increased heme-oxygenase 1 mRNA expres-
sion in endothelial cells (Fig. 4A). Simvastatin signifi-
cantly increased heme-oxygenase 1 mRNA expression in
placental explants taken from women with preterm
preeclampsia (Fig. 4B) however rosuvastatin and prava-





Fig. 2 Effect of statins on sFlt-1 secretion and sFlt-1 e15a and i13
mRNA expression from placental tissues. a Simvastatin (0, 5, 50,
100 μM), rosuvastatin (0, 50, 100, 200, 300 μM) and pravastatin (0, 20,
200, 2000 μM) reduce sFlt-1 secretion from primary trophoblasts. b
Inhibitory concentration of simvastatin, rosuvastatin and pravastatin
was determined. c Simvastatin (100 μM) and pravastatin (2000 μM)
significantly reduced sFlt-1 secretion from placental explants obtained
from patients with preterm preeclampsia however rosuvastatin had no
effect. d Pravastatin reduced sFlt-1 e15a mRNA expression from
placental explants whilst simvastatin and rosuvastatin had no effect.
Data represents n = 3-4 separate experiments and is expressed as
mean ± SEM. Dark blue bars= control, light blue bars= statin treatments.
a = p < 0.05, b = p < 0.01, d = p < 0.0001
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Discussion
Statins have been proposed as possible therapeutics for
preeclampsia. Our group [10] and Cudmore et al. [9],
have shown pravastatin and simvastatin reduced sFlt-1
secretion from placental explants and endothelial cells
respectively. The decrease in sFlt-1 caused by these sta-
tins was directly mediated through HMG CoA reductase
[9, 10]. Pravastatin is the weakest inhibitor of HMG
CoA reductase and it is conceivable that the more po-
tent inhibitors of this enzyme (simvastatin or rosuvasta-
tin) [17] may have a more pronounced effect on sFlt-1
secretion. Hence in this study, we examined the relative
potency of three generations of statins on sFlt-1
secretion.
We found simvastatin was the most potent inhibitor
of sFlt-1 secretion from all primary tissues examined. It
was 28–85 times more potent than pravastatin and
3–33 times more potent than rosuvastatin at reducing
sFlt-1 secretion from placental and endothelial cells
respectively. Whilst simvastatin is known to be a
more potent inhibitor of HMG CoA reductase than
pravastatin, it is not as potent as rosuvastatin [17].
Perhaps the more pronounced effect of simvastatin
on sFlt-1 secretion is a result of the hydrophobicity
of the molecule. In contrast to pravastatin and rosu-
vastatin, simvastatin is hydrophobic and is readily able
to cross the cellular lipid bilayer membrane [25, 26].
Therefore it is possible that this characteristic enhanced
its capacity to enter the cells and reduce sFlt-1, relative
to hydrophilic compounds, pravastatin and rosuvastatin.
This effect was particularly apparent in endothelial cells,
where simvastatin-induced a significant decrease in both
sFlt-1 e15a and sFlt-1 i13 isoforms, culminating in re-
duced sFlt-1 secretion. This is in contrast to rosuvasta-
tin, which only reduced sFlt-1 e15a, and pravastatin that
was only effective at reducing these variants at much
higher doses [9, 10].
a
b
Fig. 3 Effect of statins on soluble endoglin secretion from primary
human tissues. a Simvastatin (0, 1, 2, 5 μM), rosuvastatin (0, 1, 2, 5, μM)
and pravastatin (0, 2, 5, 200 μM) all caused an increase in soluble
endoglin secretion from primary HUVECs. b Statin treatment did
not alter sEng secretion from preterm preeclamptic explants.
Data represents n = 3–4 separate experiments and is expressed
as mean ± SEM. Dark blue bars = control, light blue bars = statin
treatments. a = p < 0.05, b = p < 0.01, d = p < 0.0001
a
b
Fig. 4 Effect of statins on heme-oxygenase 1 mRNA expression. a
Simvastatin (0, 5 μM), rosuvastatin (0, 5 μM) and Pravastatin (0,
200 μM) up-regulated heme-oxygenase 1 expression by HUVECs. b
Simvastatin 100 μM up-regulated heme-oxygenase 1 in preeclamptic
placental explants, whist pravastatin 2000 μM and rosuvastatin
100 μM had no significant effect. Data represents n = 3–4 separate
experiments and is expressed as mean ± SEM. Dark blue bars =
control, light blue bars = statin treatments. a = p < 0.05,
c = p < 0.001, d = p < 0.0001
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The effect of statins on the secretion of soluble
endoglin is concerning. We previously demonstrated
pravastatin up-regulates soluble endoglin secretion
from endothelial cells [10]. Here we demonstrate that
both simvastatin and rosuvastatin also upregulate so-
luble endoglin secretion from endothelial cells. Intri-
guingly, the effect on soluble endoglin appears also to
relate to statin potency, with simvastatin inducing the
most potent increase. Atorvastatin has previously
been shown to upregulate membrane bound endoglin
in endothelial cells, thus it is possible the increased
soluble endoglin secretion we observed is a result of
the same mechanism [27]. Reassuringly, we did not
observe an increase in soluble endoglin secretion from
preeclamptic explants treated with statins. Therefore,
we conclude that the effect statins have on soluble
endoglin secretion in vivo warrants further explo-
ration and should be measured in future studies.
Of interest, the three statins studied herein had tissue
specific effects on heme-oxygenase 1. Whilst robust up-
regulation was observed in primary endothelial cells
treated with all three classes of statins, only simvastatin
increased heme-oxygenase 1 expression in placental
explants obtained from women with preterm pre-
eclampsia. This supports the premise that heme-
oxygenase 1 may not regulate sFlt-1 secretion [28]; as
pravastatin reduced sFlt-1 secretion with no change to
heme-oxygeanse 1 expression in preterm preeclamptic
placental explants [28]. Up-regulating an antioxidant
molecule may be beneficial however and this further
supports the beneficial effects of simvastatin as a pos-
sible preeclampsia therapeutic.
Although our data suggest simvastatin is the most
potent statin at reducing sFlt-1 secretion, it is impor-
tant to note that there have been concerns regarding its
safety profile as a therapeutic for preeclampsia. This
stems from the retrospective observational study per-
formed by Edison [29] reporting an increase in limb de-
fects in fetuses exposed to simvastatin in the first
trimester. This finding has been challenged by other
large retrospective observational studies [30, 31] sho-
wing no increased risk of fetal malformation in simva-
statin exposed pregnancies compared to baseline.
Furthermore, Gibb [32] questioned the validity of
observations by Edison et al. [29] as there was no dis-
tinctive pattern to the limb defects described and the
population baseline risk was not taken into account. As
clinical onset of preeclampsia occurs in the second and
third trimester after the majority of organogenesis has
occurred, and the current treatment of preeclampsia
consists solely of delivery, inflicting high rates of death
and disability due to prematurity, we propose that the
possible benefits of simvastatin administration may out-
weigh the theoretical risk.
Conclusion
In conclusion, we have performed a direct comparison
of three different generations of statins on key biochem-
ical features of preeclampsia using primary human cells
and tissues. Simvastatin was the most potent inhibitor of
sFlt-1 secretion and the most potent agent in up-
regulating heme-oxygenase 1 expression. Therefore, it is
possible that it may be more efficacious as a treatment
for preeclampsia compared to other statins.
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